Biomednewsbreaks - Clene Inc. (NASDAQ: CLNN) Positioned As Leader In Addressing Neurodegenerative Diseases

(MENAFN- Investor Brand Network) Clene (NASDAQ: CLNN) , a biopharmaceutical company, is at the forefront of transforming the treatment of neurodegenerative disorders like amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”).“Clene's lead agent, CNM-Au8, targets the nicotinamide adenine dinucleotide ('NAD+') pathway to restore and protect neurological function. CNM-Au8 works by improving cellular energy production and utilization, which is crucial for maintaining neuronal health. Mitochondrial dysfunction is a common pathway leading to neuronal death in neurodegenerative diseases. By targeting this dysfunction, CNM-Au8 aims to provide neuroprotection and promote remyelination, potentially altering the course of these debilitating conditions,” a recent article reads.“Clene has conducted extensive clinical trials to evaluate the safety and efficacy of CNM-Au8... With over 650 years of cumulative subject exposure, CNM-Au8 has shown a strong safety profile with no serious adverse events linked to the drug... Clene is gearing up for phase three programs for both ALS and MS. The company's innovative approach, backed by strong intellectual property with over 150 patients worldwide, positions it as a leader in addressing neurodegenerative diseases.”

To view the full article, visit

About Clene Inc.

Clene (along with its subsidiaries,“Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson's disease and multiple sclerosis. CNM-Au8(R) is an investigational first-in-class therapy that improves central nervous system cells' survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8(R) is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit
.

NOTE TO INVESTORS:
The latest news and updates relating to CLNN are available in the company's newsroom at

About BioMedWire

BioMedWire
(“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the
Dynamic Brand Portfolio
@
IBN
that delivers :
(1) access to a vast network of wire solutions via
InvestorWire
to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ;
(2) article and
editorial syndication to 5,000+ outlets ;
(3) enhanced
press release enhancement
to ensure maximum impact ;
(4)
social media distribution
via IBN to millions of social media followers ;
and (5) a full array of tailored
corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire,“Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:
/Disclaimer

BioMedWire
San Francisco, CA

415.949.5050 Office
...

BioMedWire is powered by
IBN

MENAFN30082024000224011066ID1108621317